Clinical Trials e-Newsletter | April 2019

Prostate Cancer Clinical Trials Opportunities and
Life Saving Opportunities Lost
Due to Lack of African American Participation in Clinical Trials
Recent studies have shown that African-Americans with metastatic Castration Resistant Prostate Cancer exhibit greater overall survival time when treated with enzalutamide (Xtandi), abiraterone (Zytiga) or sipuleucel-T (Provenge) when compared to white patients. PHEN's April 11th webcast recognizes these major, and potentially groundbreaking findings, but points out that they came 7 and 8 years after these treatments were FDA approved due to lack of African American participation in the clinical trials for these treatments. The webcast points to this time lapse as a critical lost opportunity for men who need a survival advantage because of a prostate cancer death rate 2.3 times greater than other men, and it highlights the urgency for African American patients to become more active as clinical trial participants.

Patients Should Consider These Clinical Trials for Metastatic Prostate Cancer
Future Life-Saving Opportunities Are Happening Now!
Introducing the ProVent Clinical Trial

This clinical trial is for patients with localized prostate cancer who have not yet received any active treatment and are planning to pursue active surveillance. ProVent will evaluate the effectiveness of sipuleucel-T (Provenge) compared to active surveillance in these patients.
A Patient’s Guide to Clinical Trials
Clinical trials are a vital to healthcare for many reasons. Results from patients enrolled in these trials allow new medicines to be approved and often provides access to cutting-edge drugs that are not available to the general public. Your guide to clinical trials
PHEN’s FYT Tool Update

The Find Your Trial (FYT) Tool developed by PHEN allows you to easily search for all phase 2-4 actively-recruiting prostate cancer clinical trials. Please discover which trials may be right for you by taking a look at these FYT tool searches:
Understanding Castration Resistant Prostate Cancer

Androgen deprivation (hormone) therapy, such as Lupron, works to reduce testosterone in the body to castration levels to prevent or slow the progression of prostate cancer.

What is Castration resistant Prostate Cancer?
Prostate cancer becomes Castration Resistant when the cancer progresses despite treatment with anti-androgen therapy.

What is non-Metastatic Castration Resistant Prostate Cancer?
Castration Resistant Prostate Cancer where no metastases have been detected.

What is Metastatic Castration Resistant Prostate Cancer?
Castration Resistant Prostate Cancer that has spread and metastasized to other parts of the body such as bones and other organs.

Upcoming PHEN Events
Live Webcast: May 8th at 6 pm

"Biomarker Testing Needed Before African American
Patients Choose Active Surveillance"

This Webcast will be broadcast live from:
Dana-Farber Cancer Institute,  Boston, MA

Presenter: Todd Douglas, M.D.
VP of Medical Affairs/Medical Director of Urology
Myriad Genetics

"Daddy's Boys" Play

May 18th, 2019
Daniel Payne Community Plaza
1500 Daniel Payne Drive
Birmingham, AL

Father's Day Rally 2019

With Churches Nationwide

For more Clinical Trials Information
PHEN Clinical Trials Rally Partners
For More Information Visit